Share
Shreehas Tambe
Biocon Limited has appointed Shreehas Tambe as Chief Executive Officer and Managing Director.
The appointment follows approvals from the Board and Nomination & Remuneration Committee, marking a key milestone as the company completes the integration of Biocon Biologics Limited as a wholly owned subsidiary. Kedar Upadhye has also been appointed as Chief Financial Officer.
As the first CEO of the integrated Biocon, Tambe will lead a unified platform spanning biosimilars and generics, enhancing the company’s global competitiveness and operational scale. The strengthened organization is positioned to expand its footprint across diabetes, obesity, oncology, and immunology, supported by a diversified portfolio including biosimilars, insulins, complex generics, peptides, and GLP-1 therapies.
Tambe joined Biocon nearly three decades ago and has held multiple leadership roles across the organization. Most recently, as CEO and Managing Director of Biocon Biologics, he transformed the business into one of the world’s top five biosimilar companies by revenue, achieving a valuation of US$5.5 billion in 2025. He also led the acquisition and integration of Viatris’ biosimilars business, creating a fully integrated global biologics platform.
Earlier, he served as Chief Operating Officer and Deputy CEO, driving global expansion and operational excellence. He also played a key role in scaling the insulins business and establishing a major manufacturing facility in Malaysia. Tambe holds a Master’s degree from the University of Mumbai and is an inventor on 61 patents.
